Business
Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business
BARCELONA, May 11, 2026--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its financial results for the first quarter of 2026. Almirall continued to deliver on the company’s growth trajectory in line with expectations and the long-term strategy, led by 19.3% YoY growth of its European Dermatology business to €166.3 MM.
About this update from Almirall Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":210,"url":"https://media.zenfs.com/en/business-wire.com/82c25ba62447668458f0f0c764223b60"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.xdGP.pywSnX12gJQEi9uw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyMA--/https://media.zenfs.com/en/business-wire.com/82c25ba62447668458f0f0c764223b60","width":480,"height":210},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/PKPbDFV02M8NCwpgaQEihA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI4MA--/https://media.zenfs.com/en/business-wire.com/82c25ba62447668458f0f0c764223b60","width":480,"height":210}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Almirall's European Dermatology business delivered solid growth of 19.3% YoY, reaching €166.3 MM in Q1 2026, driven by strong momentum across key growth drivers. This contributed to overall Net Sales of €291 MM, up 2.2% YoY and reflecting 9% growth on a Last-Twelve-Months (LTM) basis.","length":289,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Performance continues to be driven by the biologics portfolio, with Ilumetri® showing 11.8% increase in sales vs Q1 2025 (total of €61.6 MM), and Ebglyss® delivering €41.9 MM quarterly sales – more than 2x YoY – boosted by sustained growth in recent launch countries.","length":267,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strong performance of the broad dermatology product portfolio in line with expectations – products driving relevance of Almirall in medical dermatology, including Wynzora® (20.8%, total of €9.3 MM) and Klisyri® (7.2%, total of €7.4 MM).","length":236,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Total EBITDA was €67.5 MM, corresponding to 23.2% over Net Sales – improvement versus FY 2025 (21%).","length":100,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Continued R&D pipeline progress includes the start of phase I of anti-IL-13/OX40L bispecific antibody, and a new collaboration with China-based biotech Huaota for the development of a novel monoclonal antibody in medical dermatology.","length":237,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reiterated guidance for the full year 2026: 9-12% growth and € 270MM to € 290MM EBITDA – sc...